DWM
RYTM icon

Dogwood Wealth Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Dogwood Wealth Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22K Hold
11
– – ﹤0.01% 748
2026
Q1 		$957 Buy
+11
New +$1.07K ﹤0.01% 759

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dogwood Wealth Management's RYTM Position: Q2 2026 in Review

Dogwood Wealth Management held its Rhythm Pharmaceuticals (RYTM) position steady in Q2 2026 at 11 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #748.

Dogwood Wealth Management first reported a position in RYTM in Q1 2026 and has held it in 2 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Dogwood Wealth Management held 11 shares of Rhythm Pharmaceuticals worth $1.22K as of Q2 2026.
  • Dogwood Wealth Management left its Rhythm Pharmaceuticals share count unchanged in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Dogwood Wealth Management's portfolio in Q2 2026, its #748 holding.
  • Dogwood Wealth Management first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Dogwood Wealth Management's 13F filing for Q2 2026, filed 6 Jul 2026.